{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-066261","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.135366+00:00","generated_at":"2026-05-24T03:15:44.371799+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Sensei Bio reports Q4 2024 cash of $41.3M; Phase 1/2 solnerstotug data shows 14% ORR in PD-(L)1 resistant tumors","bullets":["Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.","Target enrollment of 60 patients achieved in dose expansion cohort; full data expected by year-end 2025.","Net loss $30.2M for FY2024 (vs $34.1M FY2023); cash, equivalents and marketable securities $41.3M as of Dec 31, 2024, with runway into Q2 2026.","Solnerstotug well-tolerated: no dose-limiting toxicities; majority of adverse events Grade 1-2; 7% Grade 1 cytokine release syndrome.","Corporate updates: Q4 restructuring, appointment of Josiah Craver as Principal Financial Officer, and Dr. Ron Weitzman as part-time CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-066261","json":"https://secwatch.observer/filing/0001193125-25-066261.json","markdown":"https://secwatch.observer/filing/0001193125-25-066261.md","text":"https://secwatch.observer/filing/0001193125-25-066261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/0001193125-25-066261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/d927069d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:15:44.371799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}